Combined treatment with chrysin and 1,2,3,4,6-penta-O-galloyl-β-D-glucose synergistically inhibits LRP6 and Skp2 activation in triple-negative breast cancer and xenografts

Molecular Carcinogenesis

Volumn 54, Issue 12, 2015, Pages 1613-1625

  Huang, Cheng ^a   Chen, Yi Jing ^b   Chen, Wei Jen ^c,d   Lin, Chih Li ^c,d   Wei, Yu Xuan ^b   Huang, Hsiu Chen ^b  

^a NATIONAL RESEARCH INSTITUTE OF CHINESE MEDICINE   (Taiwan)

^b NATIONAL TSING HUA UNIVERSITY   (Taiwan)

^c CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^d CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

1,2,3,4,6 penta O galloyl D glucose; Chrysin; LRP6; Skp2; Triple negative breast cancer; Xenografts

Indexed keywords

1,2,3,4,6 PENTA O GALLOYL BETA DEXTRO GLUCOSE; APIGENIN; CHRYSIN; GALLIC ACID DERIVATIVE; KAEMPFEROL; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 6; QUERCETIN; S PHASE KINASE ASSOCIATED PROTEIN 2; TANNIN; UNCLASSIFIED DRUG; BETA-PENTA-O-GALLOYL-GLUCOSE; FLAVONOID; LRP6 PROTEIN, HUMAN; S PHASE KINASE ASSOCIATED PROTEIN;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER CELL LINE; CANCER COMBINATION CHEMOTHERAPY; CELL CYCLE ARREST; COLONY FORMATION; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRIPLE NEGATIVE BREAST CANCER; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; CELL CYCLE CHECKPOINT; CELL PROLIFERATION; DRUG EFFECTS; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; APOPTOSIS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; DRUG SYNERGISM; FEMALE; FLAVONOIDS; HETEROGRAFTS; HUMANS; HYDROLYZABLE TANNINS; LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN-6; MICE, INBRED BALB C; MICE, NUDE; S-PHASE KINASE-ASSOCIATED PROTEINS; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84945452415     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.22234     Document Type: Article

References (30)

1. Signoretti S, Di Marcotullio L, Richardson A, et al. Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer. J Clin Invest 2002; 110:633-641.
2. Wang Z, Fukushima H, Inuzuka H, et al. Skp2 is a promising therapeutic target in breast cancer. Front Oncol 2012; 1:18702.
3. Liu CC, Prior J, Piwnica-Worms D, Bu G. LRP6 overexpression defines a class of breast cancer subtype and is a target for therapy. Proc Natl Acad Sci USA 2010; 107:5136-5141.
4. Huang HC, Lin CL, Lin JK. 1, 2, 3, 4, 6-penta-O-galloyl-beta-D-glucose, quercetin, curcumin and lycopene induce cell-cycle arrest in MDA-MB-231 and BT474 cells through downregulation of Skp2 protein. J Agric Food Chem 2011; 59:6765-6775.
5. Nusse R, Varmus HE. Wnt genes. Cell 1992; 69:1073-1087.
6. Nusse R, Varmus H. Three decades of Wnts: A personal perspective on how a scientific field developed. EMBO J 2012; 31:2670-2684.
7. Lu W, Lin C, King TD, Chen H, Reynolds RC, Li Y. Silibinin inhibits Wnt/beta-catenin signaling by suppressing Wnt co-receptor LRP6 expression in human prostate and breast cancer cells. Cell Signal 2012; 24:2291-2296.
8. Nakayama K, Nagahama H, Minamishima YA, et al. Targeted disruption of Skp2 results in accumulation of cyclin E and p27(Kip1), polyploidy and centrosome overduplication. EMBO J 2000; 19:2069-2081.
9. Fagan-Solis KD, Pentecost BT, Gozgit JM, et al. SKP2 overexpression is associated with increased serine 10 phosphorylation of p27 (pSer10p27) in triple-negative breast cancer. J Cell Physiol 2014; 229:1160-1169.
10. Tang Y, Simoneau AR, Liao WX, et al. WIF1, a Wnt pathway inhibitor, regulates SKP2 and c-myc expression leading to G1 arrest and growth inhibition of human invasive urinary bladder cancer cells. Mol Cancer Ther 2009; 8:458-468.
11. Huang C, Lee SY, Lin CL, et al. Co-treatment with quercetin and 1, 2, 3, 4, 6-penta-O-galloyl-beta-D-glucose causes cell cycle arrest and apoptosis in human breast cancer MDA-MB-231 and AU565 cells. J Agric Food Chem 2013; 61:6430-6445.
12. Hong TB, Rahumatullah A, Yogarajah T, Ahmad M, Yin KB. Potential effects of chrysin on MDA-MB-231 cells. Int J Mol Sci 2010; 11:1057-1069.
13. Kuo PT, Lin TP, Liu LC, et al. Penta-O-galloyl-beta-D-glucose suppresses prostate cancer bone metastasis by transcriptionally repressing EGF-induced MMP-9 expression. J Agric Food Chem 2009; 57:3331-3339.
14. Chen WJ, Lin JK. Induction of G1 arrest and apoptosis in human jurkat T cells by pentagalloylglucose through inhibiting proteasome activity and elevating p27Kip1, p21Cip1/WAF1, and Bax proteins. J Biol Chem 2004; 279:13496-13505.
15. Spoerlein C, Mahal K, Schmidt H, Schobert R. Effects of chrysin, apigenin, genistein and their homoleptic copper(II) complexes on the growth and metastatic potential of cancer cells. J Inorg Biochem 2013; 127:107-115.
16. Yang B, Huang J, Xiang T, et al. Chrysin inhibits metastatic potential of human triple-negative breast cancer cells by modulating matrix metalloproteinase-10, epithelial to mesenchymal transition, and PI3K/Akt signaling pathway. J Appl Toxicol 2014; 34:105-112.
17. Xie QW, Kashiwabara Y, Nathan C. Role of transcription factor NF-kappa B/Rel in induction of nitric oxide synthase. J Biol Chem 1994; 269:4705-4708.
18. Brechbuhl HM, Kachadourian R, Min E, Chan D, Day BJ. Chrysin enhances doxorubicin-induced cytotoxicity in human lung epithelial cancer cell lines: The role of glutathione. Toxicol Appl Pharmacol 2012; 258:1-9.
19. Rashid S, Ali N, Nafees S, et al. Alleviation of doxorubicin-induced nephrotoxicity and hepatotoxicity by chrysin in Wistar rats. Toxicol Mech Methods 2013; 23:337-345.
20. Lu D, Choi MY, Yu J, Castro JE, Kipps TJ, Carson DA. Salinomycin inhibits Wnt signaling and selectively induces apoptosis in chronic lymphocytic leukemia cells. Proc Natl Acad Sci USA 2011; 108:13253-13257.
21. Sonoda H, Inoue H, Ogawa K, Utsunomiya T, Masuda TA, Mori M. Significance of skp2 expression in primary breast cancer. Clin Cancer Res 2006; 12:1215-1220.
22. Chan CH, Li CF, Yang WL, et al. The Skp2-SCF E3 ligase regulates Akt ubiquitination, glycolysis, herceptin sensitivity, and tumorigenesis. Cell 2012; 149:1098-1111.
23. Lin SY, Xia W, Wang JC, et al. Beta-catenin, a novel prognostic marker for breast cancer: Its roles in cyclin D1 expression and cancer progression. Proc Natl Acad Sci USA 2000; 97:4262-4266.
24. Lu W, Lin C, Li Y. Rottlerin induces Wnt co-receptor LRP6 degradation and suppresses both Wnt/beta-catenin and mTORC1 signaling in prostate and breast cancer cells. Cell Signal 2014; 26:1303-1309.
25. Lu W, Lin C, Roberts MJ, Waud WR, Piazza GA, Li Y. Niclosamide suppresses cancer cell growth by inducing Wnt co-receptor LRP6 degradation and inhibiting the Wnt/beta-catenin pathway. PLoS ONE 2011; 6:e29290.
26. Mason JJ, Williams BO. SOST and DKK: Antagonists of LRP family signaling as targets for treating bone disease. J Osteoporos 2010; 1:460120.
27. Ren S, Johnson BG, Kida Y, et al. LRP-6 is a coreceptor for multiple fibrogenic signaling pathways in pericytes and myofibroblasts that are inhibited by DKK-1. Proc Natl Acad Sci USA 2013; 110:1440-1445.
28. Rey JP, Ellies DL. Wnt modulators in the biotech pipeline. Dev Dyn 2010; 239:102-114.
29. Wu MS, Lien GS, Shen SC, Yang LY, Chen YC. N-acetyl-L-cysteine enhances fisetin-induced cytotoxicity via induction of ROS-independent apoptosis in human colonic cancer cells. Mol Carcinog 2014; 53:E119-E129.
30. Li Y, Lu W, He X, Schwartz AL, Bu G. LRP6 expression promotes cancer cell proliferation and tumorigenesis by altering beta-catenin subcellular distribution. Oncogene 2004; 23:9129-9135.